Carbon Material Hybrid Construction on an Aptasensor for Monitoring Surgical Tumors

Abstract

Carcinoembryonic antigen (CEA) is a glycoprotein, one of the common tumor biomarkers, found at low levels in body fluids. Generally, overexpression of CEA is found in various cancers, including ovarian, breast, lung, colorectal, gastric, and pancreatic cancers. Since CEA is an important tumor biomarker, the quantification of CEA is helpful for diagnosing cancer, monitoring tumor progression, and the follow-up treatment. This research develops a highly sensitive sandwich aptasensor for CEA identification on an interdigitated electrode sensor. Carbon-based material was used to attach a higher anti-CEA capture aptamer onto the sensor surface through a chemical linker, and then, CEA was quantified by the aptamer. Furthermore, CEA-spiked serum was tested by using the immobilized aptamer, which was found to not affect the target validation. The limit of detection for CEA in PBS and serum is calculated from a linear regression graph to be 0.5 ng/mL with R2 values of 0.9593 and 0.9657, respectively, over a linear range from 0.5 to 500 ng/mL. This CEA quantification by the aptasensor can help diagnose various surgical tumors and monitor their progression.

Predicting Analyte Concentrations from Electrochemical Aptasensor Signals Using LSTM Recurrent Networks

“…Thus, advanced nanostructured materials have been utilized to improve the sensing capacities of aptasensors [ 6 ], lower the limits of detection of analytes [ 7 ], and amplify the sensors’ signals [ 8 ]. Nanomaterial-based aptasensors have been used as effective instruments for recognizing small analytes in clinical health diagnostics [ 6 , 7 ], medical therapy [ 9 ], and disease biomarker detection [ 10 ]. In addition, using and improving these analytical devices for identifying and quantifying a target analyte is beneficial due to their having higher specificity and selectivity and their elimination of labor-intensive and time-consuming procedures, expensive instruments, and multiple analytical steps [ 11 ].…”

Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer

“…Additionally, immobilized aptamers were used in the CEA blood tests, which did not alter the target validation. The CEA detection limit in PBS and serum was determined to be 0.5 ng/mL [ 83 ].…”